LSU Health Shreveport has established the Emerging Viral Threat (EVT) Laboratory to address the need for faster detection and processing of COVID-19 tests.
LSUHS leadership, faculty, staff, students and community supporters recently honored the continued growth of research initiatives and funding at the second annual Research Celebration event held on February 25, 2020.
Cherie-Ann O. Nathan, MD is the lead author of a study that found a targeted therapy drug used for breast and kidney cancers may also extend survival for patients with advanced head and neck cancer.
Internationally recognized for his research on inflammatory vascular pathology, specifically on and the relationship between inflammation and vascular growth and function, Dr. Kevil discovered detailed mechanistic relationships between angiogenesis and inflammation.
Three Fellows in the Department of Pathology and the Center for Cardiovascular Diseases and Sciences have been awarded Fellowships funding their ongoing research into cardiovascular diseases.
Aphios Granted U.S. Patent for Oral Administration of Bryostatin-1 Nanoparticles for Treatment of Neurodegenerative Diseases, which was co-invented by LSU Health Shreveport professor, Dr. J. Steven Alexander.
JanOne Acquires Worldwide, Exclusive License for Promising Treatment of Peripheral Arterial Disease (PAD), TV1001SR, which was invented by LSU Health Shreveport professor and vice chancellor for research, Dr. Chris Kevil.
The Medical Student Research Program provides medical students with the opportunity to gain additional experience in research.
Praveen K. Jaiswal, PhD, a postdoctoral fellow in the Department of Biochemistry and Molecular Biology has received a prestigious Research Scholar Award for Mentored Prostate Cancer Research from the AUA Urology Care Foundation.
Research and Industry Day (RAID) was hosted at LSU Health Shreveport on October 11.